Unknown

Dataset Information

Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development.


ABSTRACT:

Background

Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family inhibitor undergoing parallel clinical development for alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis.

Objective

As studies read out simultaneously, strategic planning of population pharmacokinetic model development and evaluation is required to ensure timely decisions.

Methods

Data from healthy participants and patients from 12 clinical trials between December 2014 and July 2021 were included: seven phase I studies in healthy participants and organ impairment, five phase II/III studies in patients with rheumatoid arthritis, ulcerative colitis, alopecia areata, and vitiligo. Population pharmacokinetic models consisted

SUBMITTER: Wojciechowski J 

PROVIDER: S-EPMC10684409 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature